Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs HealthSource

AM Rx
Graded #491

Lower grade

vs+21.6
HealthSource
Graded #97

Higher grade

The verdict

HealthSource takes it — 71.2/100 to 49.6/100.

HealthSource grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthSource is a telehealth weight-management platform offering compounded semaglutide and tirzepatide (injectable and oral sublingual) dispensed through a US-based FDA 503A licensed partner pharmacy.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHealthSource +16
50
66
Dose & formulationHealthSource +18
65
83
Clinical oversightHealthSource +39
41
80
Labs & monitoringHealthSource +5
49
54
FulfillmentHealthSource +22
58
80
Contract termsHealthSource +35
20
55
AM Rx · left barHealthSource · right bar

The numbers

MetricAM RxHealthSource
WeighScore49.6/10071.2/100
GradeCC
Scorecard rank#491#97
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)$199/mo (all doses, compounded)
TirzepatideNot disclosed$299/mo (all doses, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
AM Rx

Graded #491 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
HealthSource

Graded #97 · C

Strengths

  • Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
  • 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
  • Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
  • Subscription auto-refund if monthly reassessment is not completed
  • Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping

Where it loses points

  • No physician names or clinical leadership disclosed on public pages
  • No LegitScript certification found
  • 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
  • Labs not mentioned on any product page — baseline bloodwork protocol unknown
  • WooCommerce e-commerce storefront may feel more transactional than clinical

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard